David Benjamin MD

PubMed

• Implications and Lessons from the Withdrawal of Sacituzumab Govitecan for Treating Advanced Urothelial Carcinoma.
  David J Benjamin, Arash Rezazadeh Kalebasty, Nataliya Mar
  European Urology Oncology. 2025-04-01
• 1 citations
  Pairing the Right Individual with the Right Regimen: Patient Selection Criteria in the Treatment of Advanced Urothelial Carcinoma.
  David J Benjamin, Arash Rezazadeh Kalebasty
  European Urology Oncology. 2025-04-01
• Sexual health and reproductive toxicity from cancer therapies.
  David J Benjamin, Mark P Lythgoe
  The Lancet. Oncology. 2025-04-01

Abstracts/Posters

• State of the genitourinary medical oncology workforce in the United States, 2024
  David Joseph Benjamin, Arash Rezazadeh, ASCO Genitourinary Cancers Symposium, San Francisco, CA, 2/15/2025
• Characterization of genitourinary drug approvals by the FDA, 2020-2024
  David Joseph Benjamin, Arash Rezazadeh, ASCO Genitourinary Cancers Symposium, San Francisco, CA, 2/14/2025
• State of Supportive Care in Oncology, 2024: Tumor Types, Industry Support, Endpoints, and Trial Locations
  David J Benjamin, Arash Rezazadeh Kalebasty, ESMO Congress 2024, Barcelona, Spain, 9/15/2024
• As Seen Through Hollywood's Lens: Cancer in Movies, 2010-2020
  David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty, ESMO Congress 2024, Barcelona, Spain, 9/15/2024
• Comprehensive Analysis of Targetable Alterations in Urachal Cancer by NGS
  Benjamin DJ, Adeyelu TT, Darabi S, Lee T, McKay RR, Oberley MK, Rezazadeh A, Elliott A, ASCO Genitourinary Cancers Symposium, San Francisco, CA, 1/26/2024
• Testicular cancer: Trends in incidence and demographics from 23,214 cases in California from 2000-2020
  D.J. Benjamin, A. Shrestha, D. Fellman, A. Rezazadeh Kalebasty, ESMO Congress 2023, Madrid, Spain, 10/23/2023
• Characterization and survival benefit of drugs approved for advanced renal cell carcinoma
  David Joseph Benjamin, Arash Rezazadeh, ASCO Genitourinary Cancers Symposium, San Francisco, CA, 2/18/2023
• Characterization and survival benefit of drugs approved for metastatic prostate cancer
  David Joseph Benjamin, Arash Rezazadeh, ASCO Genitourinary Cancers Symposium, San Francisco, CA, 2/17/2023
• Urachal cancer: A population-based study of 315 cases in California from 1988-2019
  David J Benjamin, Anshu Shrestha, Dimitra Fellman, Rosemary Cress, Arash Rezazadeh Kalebasty, ESMO Congress 2022, Paris, France, 9/12/2022
• Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study of 15,435 cases from the California Cancer Registry (2009-2018).
  David Joseph Benjamin, Dimitra Fellman, Anshu Shrestha, Arash Rezazadeh, ASCO Genitourinary Cancers Symposium, 1/17/2022
• The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospect...
  Karen Kelly, Shuai Chen, Joanna B Eldredge, David Joseph Benjamin, Matthew C Mulroy, Nadeem Tabbara, John Sharp, Jonathan Wade Goldman, Matthew A. Gubens, Jeremy P. Ha..., 2021 ASCO Annual Meeting, 6/4/2021
• Retrospective Analysis of Adults with Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
  Tenold M, Moskoff B, Benjamin D, Jonas BA, 60th Annual American Society of Hematology Meeting and Exposition, San Diego, CA, 11/29/2018
• Efficacy of Single-Agent Pemetrexed in Platinum Refractory Metastatic Urothelial Cancer
  Benjamin DJ, Bambury RM, Chaim JL, Zabor EC, Ostrovnaya I, Garcia-Grossman IR, Iyer G, Bajorin DF, and Rosenberg JE, ASCO Genitourinary Cancers Symposium, San Francisco, CA, 1/31/2014
• Join now to see all

Lectures

• Retrospective Analysis of Treatment Initiation and Treatment Delay in Metastatic Renal Cell Carcinoma 
  DAVA Oncology 7th Annual Summit on Genitourinary Malignancies. Colorado Springs, CO - 11/24/2024
• The Role of Maintenance Avelumab: a 2024 Perspective 
  DAVA Oncology 7th Annual Summit on Genitourinary Malignancies, Colorado Springs, CO - 11/23/2024
• A Population-Based Study of Incidence and Survival Trends of 1,588 Thymic Malignancies (TM): Results from the California Cancer Registry (CCR) 
  IASLC 19th World Conference on Lung Cancer, Toronto, Canada - 9/25/2018